

Patient Name: _____
DOB: _____

LECANEMAB-IRMB (LEQEMBI™) INFUSION ORDERS

1	Diagnosis:		
	<input type="checkbox"/> G30.0 Alzheimer's Disease, Early Onset <input type="checkbox"/> G30.1 Alzheimer's Disease, Late Onset <input type="checkbox"/> G30.8 Other Alzheimer's disease <input type="checkbox"/> G30.9 Alzheimer's disease, unspecified <input type="checkbox"/> G31.84 Mild Cognitive Impairment, So Stated	← G30.X codes require secondary F02.8X code →	<input type="checkbox"/> F02.80 Dementia without behavioral disturbance <input type="checkbox"/> F02.81 Dementia with behavioral disturbance <input type="checkbox"/> Other: _____ (ICD-10 Code)(Description)
	Gender: <input type="checkbox"/> M <input type="checkbox"/> F	Height: <input type="checkbox"/> CM <input type="checkbox"/> IN	Weight: <input type="checkbox"/> KG <input type="checkbox"/> LB
2	Prescriber must indicate the following requirements have been met (please provide documentation):		
	<input type="checkbox"/> Beta Amyloid Pathology Confirmed Via:		
	<input type="checkbox"/> Amyloid PET Scan Date: _____ OR <input type="checkbox"/> CSF Analysis Date: _____ Result: _____		
3	<input type="checkbox"/> Cognitive Assessment Used: _____ Date: _____ Result: _____		

- Pre-Infusion:**
- Confirm baseline MRI results prior to initiation of treatment.
 - Confirm MRI completed and reviewed by prescriber prior to the 5th, 7th, and 14th treatment.
 - Measure and record weight prior to each treatment to determine dose.
 - Hold infusion and notify provider if patient reports:
 - Headache.
 - Dizziness.
 - Nausea.
 - Vision changes.
 - New or worsening confusion.

Medication:	<input checked="" type="checkbox"/> Administer LEQEMBI 10 mg/kg intravenously over at least 60 minutes.
<input checked="" type="checkbox"/> Dilute required volume of lecanemab-irmb in 250 ml 0.9% sodium chloride and infuse using a terminal low-protein binding 0.2-micron in-line filter.	
<input checked="" type="checkbox"/> If infusion-related reaction occurs, stop infusion and treat per orders/protocol as clinically indicated.	

- Treatment Frequency**
- Schedule treatments every two weeks (at least 14 days apart).

- Post-Infusion:**
- Educate patient/care partner to report headache, dizziness, nausea, vision changes, or new/worsening confusion.
 - Fax treatment notes to provider at number below:

Prescriber name (print): _____
Fax: _____
Prescriber signature: _____
Date: _____